Journal
Journal for Immunotherapy of Cancer
Publication Date
1-22-2026
Volume
14
Issue
1
First Page
e011284
Document Type
Open Access Publication
DOI
10.1136/jitc-2024-011284
Rights and Permissions
Le DT, Folprecht G, Varghese AM, Gutierrez M, Noel M, Trikalinos NA, Chen E, Dayyani F, Davis SL, Ma WW, BasuMallick A, Garrido-Laguna I, Osawa M, O'Brien S, Novosiadly RD, Xu K, Greenawalt DM, Dutta S, Twyman Saint Victor C, Lenz HJ. Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer. J Immunother Cancer. 2026 Jan 22;14(1):e011284. doi: 10.1136/jitc-2024-011284.This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license
Recommended Citation
Le, Dung T; Trikalinos, Nikolaos A; and et al., "Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer." Journal for Immunotherapy of Cancer. 14, 1. e011284 (2026).
https://digitalcommons.wustl.edu/oa_4/6264
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
